BioSpace News Archive

Agreement extends Smith+Nephew’s ‘Positive Connections’ program to offer ASC customers educational, advisory and financial services

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s Investigational New Drug application (“IND”) to initiate a Phase 2 proof-of-concept study to evaluate the therapeutic poten

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today it has enrolled 22 patients in

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2020 financial results on Tuesday, May 12, 2020 , after the close of US markets. Management will host a conference call on the same day a

MyMyopia™ is a disease awareness effort that shares important information with parents and eye care professionals on the growing childhood myopia epidemic.

PTC Therapeutics, Inc. announced that management will present in a virtual format at the following conferences

Insmed Incorporated announced that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public of $23.25 per share.

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of Adrian Adams , who served as Chairman of the Board of Directors since

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2020 financial results on Thursday, May 14, 2020. Compa

Portage Biotech Inc. (“Portage” or the “Company”) wishes to provide an update on a subsidiary company, Saugatuck Therapeutics Ltd. (“Saugatuck”). Portage Biotech Inc. holds an 70% equity interest in Saugatuck. Portage is pleased to announce that initial proof of concept of the n